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Absolute measurement of the tissue origins
of cell-free DNA in the healthy state and
following paracetamol overdose
Danny Laurent1, Fiona Semple1, Philip J. Starkey Lewis2, Elaine Rose1, Holly A. Black1, Jennifer Coe1,
Stuart J. Forbes2, Mark J. Arends3, James W. Dear4 and Timothy J. Aitman1*
Abstract
Background: Despite the emergence of cell-free DNA (cfDNA) as a clinical biomarker in cancer, the tissue origins of
cfDNA in healthy individuals have to date been inferred only by indirect and relative measurement methods, such
as tissue-specific methylation and nucleosomal profiling.
Methods: We performed the first direct, absolute measurement of the tissue origins of cfDNA, using tissue-specific
knockout mouse strains, in both healthy mice and following paracetamol (APAP) overdose. We then investigated
the utility of total cfDNA and the percentage of liver-specific cfDNA as clinical biomarkers in patients presenting
with APAP overdose.
Results: Analysis of cfDNA from healthy tissue-specific knockout mice showed that cfDNA originates predominantly
from white and red blood cell lineages, with minor contribution from hepatocytes, and no detectable contribution
from skeletal and cardiac muscle. Following APAP overdose in mice, total plasma cfDNA and the percentage
fraction originating from hepatocytes increased by ~ 100 and ~ 19-fold respectively. Total cfDNA increased by an
average of more than 236-fold in clinical samples from APAP overdose patients with biochemical evidence of liver
injury, and 18-fold in patients without biochemically apparent liver injury. Measurement of liver-specific cfDNA,
using droplet digital PCR and methylation analysis, revealed that the contribution of liver to cfDNA was increased
by an average of 175-fold in APAP overdose patients with biochemically apparent liver injury compared to healthy
subjects, but was not increased in overdose patients with normal liver function tests.
Conclusions: We present a novel method for measurement of the tissue origins of cfDNA in healthy and disease
states and demonstrate the potential of cfDNA as a clinical biomarker in APAP overdose.
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Background
In 1948, Mandel and Metaìs described the presence of
DNA in plasma [1], now known as cell-free DNA
(cfDNA) and known to be present in other bodily fluids,
such as urine [2], saliva and cerebrospinal fluid [3].
Release of cfDNA into the circulation is likely due to
cellular breakdown mechanisms, such as apoptosis and
necrosis, as well as active DNA release mechanisms [4].
The size profile of cfDNA typically follows multiples of
the ~ 180 bp nucleosomal unit [5, 6], with a dominant
peak size of 167 bp [7].
Analysis of cfDNA is clinically useful for detecting
genetic and epigenetic alterations in DNA by allowing
repeated non-invasive or minimally invasive sampling
from bodily fluids [8]. Analysis of foetal cfDNA in ma-
ternal plasma has been clinically implemented for non-
invasive prenatal testing of chromosomal abnormalities
and some monogenic disorders [9, 10]. Analysis of
cfDNA in cancer genomics is evolving rapidly [11–14]
and utility of cfDNA as a biomarker of internal tissue
damage [15–17], in organ transplantation [18] and in
autoimmune disease is being investigated [19, 20].
Despite these developments, the tissue origins of
cfDNA are not yet completely known. Current under-
standing rests on indirect and relative measurement
methods, such as tissue-specific methylation markers
[21–23] and nucleosomal profiling [7], with substantial
variations in the estimated proportions of the tissues of
origin between different studies [24]. Here, we present
the first absolute, direct measurement of the tissue
origins of cfDNA using six tissue-specific knockout
mouse strains. We demonstrate that hepatocytes are a
minor contributor to the pool of circulating cfDNA in
healthy mice, and show a substantial increase in
hepatocyte-derived cfDNA in mice exposed to an over-
dose of paracetamol (also known as acetaminophen,
acetyl-para-aminophenol or APAP). Ultimately, we dem-
onstrate the potential of cfDNA as a clinical biomarker
in APAP overdose in human subjects. Overall, our find-
ings form an important foundation for the development
of cfDNA-based assays as biomarkers in non-malignant
human disease.
Methods
Generation of tissue-specific knockout mice
Absolute measurement of the tissue origins of cfDNA in
healthy mice was achieved by analysing cfDNA from
tissue-specific knockout mice. cfDNA originating from
the cells of interest, which express Cre recombinase
from a cell-specific promoter, were recombined (1lox),
as opposed to unrecombined (2lox) from other cell
types in the body that do not express Cre recombin-
ase (Additional File 1: Figure S1). For this study, a
conditional mutation in the floxed mT/mG dual
reporter gene [25] was generated in C57BL/6 mice by
crossing mice homozygous for the floxed mT/mG
gene with mice expressing different cell/tissue-specific
Cre recombinase to obtain cell/tissue-specific knockout F1
mice. Myeloid (LysMCre) [26], lymphoid (hCD2-iCre) [27],
cardiomyocyte (cTnTCre) [28], hepatocyte (AlbCre) [29]
and striated muscle (MCKCre) [30] Cre mice were obtained
from the Jackson laboratory. Erythroid (EpoRCre) [31] mice
were obtained from Prof. Stuart Orkin (Cooperative
Centers of Excellence in Hematology, Bostons Children’s
Hospital). Mouse breeding was carried out in individually
ventilated cages (4–6 mice per cage depending on litter
size) with constant access to food and water, in the Bio-
medical Research Facility (BRF), University of Edinburgh
(UoE) under Home Office project license PPL P1070AFA9
and genotyping was performed by Transnetyx (Cordova,
Tennessee, USA) to confirm the presence of Cre recombin-
ase and the floxed mT/mG gene. A total of 91 male tissue-
specific knockout mice (F1, n > 10 for each knockout line,
Additional File 2: Figure S2) were culled at 10–12 weeks
old via exposure to gradually increasing concentrations of
carbon dioxide gas (schedule 1 method) at 10% displace-
ment rate (chamber volume / minute). Carbon dioxide flow
was continued for 1–2min after cessation of breathing. No
anaesthetic agent was used in the study. Blood was col-
lected post-mortem from the inferior vena cava using 1ml
syringes with a 25G needle into EDTA tubes. Plasma was
obtained by centrifugation of blood at 1000 g for 10min,
then 16,000 g for 5min, within 3 h of blood collection. Tis-
sue samples were collected from mice post-mortem and
stored at − 70 °C prior to analysis.
Induction of APAP overdose in mice
Mice were fasted 12 h prior to intraperitoneal (IP) injec-
tion with APAP (350mg/kg mouse body weight), main-
tained in a 30 °C incubator and given semi-solid food.
Experiments were carried out under the Home Office pro-
ject license PPL 70/7847. To investigate the timepoint
where cfDNA concentration is highest following APAP
overdose, culling and plasma collection were performed at
8, 24 and 48 h following APAP injection in C57BL/6 mice
(Charles River Laboratories, UK; n = 4 per time point).
Contribution of hepatocytes to cfDNA levels was deter-
mined at 8 h post APAP injection in hepatocyte-specific
knockout mice (n = 4). Negative control mice injected
with saline were included in each experiment. Mouse
treatments were assigned prior to measurement of mouse
body weight with restricted randomisation (each cage con-
tained APAP and saline injected mice). Dosing for all mice
was performed during the day within an hour. Mouse eu-
thanasia was performed by exposure to increasing concen-
trations of carbon dioxide gas (as above). To confirm
tissue damage from APAP dosing, liver tissues were sec-
tioned and stained with hematoxylin and eosin (H&E) at
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the Pathology Department, UoE, and liver function tests
(alanine aminotransferase / ALT, aspartate aminotransfer-
ase/AST, albumin (ALB), bilirubin) were performed on
plasma samples at the Shared University Research Facility,
UoE.
Clinical samples
Serum was collected from healthy volunteers (n = 11)
and APAP overdose patients(n = 8) from the SNAP Clin-
ical Trial [32]. All study subjects were over the age of 16
years and gave written informed consent. The overdose
group was comprised of two groups: normal ALT (n = 4)
and raised ALT (n = 4), indicating clinical/biochemically
apparent liver injury. Additionally, paired serum samples
from three APAP overdose patients before and 20–40 h
after treatment with N-acetylcysteine (NAC, 500-900 mg
NAC/kg of patient body weight) were analysed to show
changes in biomarker levels before and after treatment.
Blood samples were centrifuged at 1000 g for 15 min at
4 °C and the supernatant was separated into aliquots and
stored at − 80 °C prior to analysis. The protocol was ap-
proved by the Scotland A Research Ethics Committee,
UK (ref no 10/MRE00/20).
Genomic and cell-free DNA extraction and quantitation
Genomic DNA (gDNA) was extracted from frozen tissue
samples using DNEasy blood and tissue kit (QIAGEN)
and quantified using the Qubit dsDNA Broad Range
assay kit (Thermo Fisher Scientific) according to manu-
facturer’s instructions. cfDNA was extracted from
plasma using the QIAamp circulating nucleic acid kit
(QIAGEN) according to the manufacturer’s instructions.
cfDNA from clinical samples and mice was quantified
using a single locus qPCR assay on the beta-actin (ACTB
/ Actb) gene [33, 34]. Fragment analysis of cfDNA was
performed using Agilent DNA Bioanalyser.
Droplet-digital PCR assay design and validation
A probe-based droplet-digital PCR (ddPCR) assay was
designed to quantify the 1lox and 2lox mT/mG alleles.
The assay was adapted from a probe-based qPCR assay
[35] and designed using Primer3 [36] following the
Biorad ddPCR application guide, with a maximum
amplicon size of 130 bp to accommodate for small frag-
ments of cfDNA. The assay was validated by amplifica-
tion of gDNA containing only 1lox or 2lox DNA
fragments by ddPCR (Additional File 3: Table S1).
Visualisation of Cre recombination with fluorescence
imaging and histological analysis of tissue samples
Fluorescence microscopy of frozen tissue sections from
knockout mice was performed to visually confirm Cre
recombination in tissues, based on expression of cell
membrane-localised enhanced green fluorescent protein
(mG) and cell membrane-localised tdTomato (mT). Sec-
tions of 5 μm were obtained from frozen tissues using a
cryostat. These sections were put on a slide with mount-
ing medium prolong gold and DAPI to stain nuclear
DNA and left overnight at 4 °C. Sectioning and staining
were performed in the Pathology Department, UoE.
Slides were visualised using a Britemac epifluorescence
microscope in the Institute of Genetics and Molecular
Medicine (IGMM) Advanced Imaging Facility, UoE, with
non-fluorescent frozen tissue slides from C57BL/6 mice
as a negative control for tissue autofluorescence.
Analysis of Cre recombination in genomic DNA and cell-
free DNA
Cre recombination was analysed in gDNA of tissue-
specific knockout mice using ddPCR to ensure successful
recombination in the target tissue and check for specificity
of Cre recombination in non-target tissues. Analysis of
Cre recombination in the cfDNA of tissue-specific knock-
out mice was performed to show the contribution of the
corresponding Cre-driven cell/tissue types to cfDNA. An
input of 10 ng of cfDNA was required for each well of
ddPCR. Amplification of 1lox and 2lox alleles were per-
formed in separate wells. Each sample was measured at
least in triplicate. The amplification was run on a thermal
cycler as follows: 10min of activation at 95 °C, 40 cycles of
a two-step amplification protocol (30s at 94 °C denatur-
ation and 60s at 60 °C), and a 10-min inactivation step at
98 °C. The metric used to show Cre recombination was
percentage recombination (1lox%).
1lox% ¼ total 1lox allele
1loxþ 2lox allele 100%
Analysis of liver-specific methylation fragments in human
cfDNA
The contribution of liver tissue to cfDNA in clinical
samples was analysed using a methylation-specific
ddPCR assay [37] on bisulphite-converted cfDNA using
the Epitect DNA bisulphite conversion kit (QIAGEN).
The assay consisted of a mixture of primer pairs and
probes (Additional File 4: Table S2) that specifically
amplified a methylated (from liver) and unmethylated
(from other tissues) region in the PTK2B gene (chr8: 27,
183,116-27,183,176, hg19). The amplification reaction
was run on a thermocycler as follows: 10 min of de-
naturation at 95 °C, 45 cycles of a two-step amplification
(94 °C for 15 s and 60 °C for 60s), and a 10-min inactiva-
tion step at 98 °C.
Statistics
For the comparison of cell-free DNA in the healthy
states from different tissue-specific knockout lines,
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plasma from at least 10 mice were pooled for cfDNA to
extraction. Measurement was performed on the ddPCR
platform in a single experiment with three technical rep-
licates for each knockout line. Analysis of cfDNA follow-
ing APAP overdose in mice was performed in a single
ddPCR experiment with four biological replicates and
three technical replicates. Analysis of cfDNA from APAP
overdose patients was performed on individual samples
(n = 19) in a single experiment. Non-parametric statis-
tical methods were performed on datasets to account for
small sample sizes, the presence of data outliers, and
data distribution that was not normal. Normality of data
distribution was confirmed using Shapiro-Wilk test. The
presence of outliers in datasets were confirmed using
graphical examination of boxplots. A Mann-Whitney U
test were performed to compare biomarker measure-
ments between different groups of clinical samples, and
to compare percentage of recombination of the floxed
mT/mG gene in mouse tissues. Statistical dependence
between biomarkers in clinical samples were assessed
using Spearman’s rank correlation coefficient.
Results
Validation of ddPCR assay for absolute quantification of
cfDNA tissue origins
We designed and validated a ddPCR assay to quantify
recombination in the floxed mT/mG gene. Amplification
of gDNA was performed to demonstrate specificity for
each target allele (Fig. 1a and b). Amplification of 2 lox
gDNA with the 1lox assay showed no positive droplet
(Fig. 1a). Amplification of the 1lox gDNA with the 2lox
assay showed 13 positive droplets out of a total of 16,
467 (less than 0.1%) (Fig. 1b). Assay sensitivity was
tested using a dilution series of target alleles to show
that the assay reproducibly quantifies less than 30
target alleles (Fig. 1c). Non-specific amplification was
not observed in C57BL/6 background gDNA, nor in the
water negative control.
Analysis of DNA recombination in mouse tissues
Cre recombination was confirmed in expected tissues
using ddPCR (Fig. 2a) and fluorescence microscopy
based on the expression of the mT/mG reporter gene
(Fig. 2b). To check for specificity of Cre recombination,
we performed ddPCR on gDNA extracted from 16 tissue
types for each knockout line. Highest specificity was
found in hepatocyte and cardiomyocyte knockout lines,
where recombination was observed in liver and heart, re-
spectively, with minimal recombination in other tissues
(Fig. 2c). Specificity of Cre recombination was more
variable, but generally lower in the other knockout lines
(Additional File 5: Figure S3).
Tissue origins of cfDNA in healthy mice
To determine the tissue origins of cfDNA, we analysed
cfDNA from the six tissue-specific knockout lines using
ddPCR. Plasma from 10 or more mice for each knockout
line was pooled prior to cfDNA extraction, to account
for the small circulating blood volume of individual
mice and the low physiological concentration of cfDNA
(Additional File 6: Figure S4). Sufficient DNA was
extracted for triplicate measurements of the pooled
sample from each line by ddPCR (Fig. 3a). DNA frag-
ment analysis confirmed the expected cfDNA fragment
size profile which followed the mono-, di- and tri-
nucleosome pattern associated with apoptosis, with lar-
ger cfDNA fragments most likely due to tissue necrosis
and lysis (Fig. 3b).
Contribution of different cell types to cfDNA was
quantified by counting the number of 1lox and 2lox
alleles in the cfDNA of mice for each knockout line and
subsequently the percentage recombination (1lox%) for
each of the knockout lines was calculated (Fig. 3c).
Absolute measurement of cfDNA showed that myeloid,
lymphoid and erythroid lineages were the major contrib-
utors to the levels of cfDNA in healthy mice, contribut-
ing 39.7, 27.8 and 10.7% respectively, with a small
contribution from hepatocytes (4.2%). Both cardiomyo-
cyte and striated muscle cells had undetectable contri-
bution to the levels of cfDNA (Fig. 3d). A comparison
of these findings with two other studies in human
using methylation pattern confirmed haematopoietic
cells as major contributors to cfDNA in the healthy
state (Additional File 7: Table S3).
Tissue origins of cfDNA following tissue injury in mice
To validate tissue-specific knockout mice as a model
system for studying the tissue origins of cfDNA, we
measured hepatocyte-specific cfDNA levels after APAP
overdose in hepatocyte-specific knockout mice. The op-
timal timepoint for sample collection was determined
using C57BL/6 mice after APAP administration. Follow-
ing APAP administration, mice developed phenotypic
signs of acute liver injury, characterised by hunched pos-
ture, with no severe signs of liver injury, including loss
of mobility or abnormal respiration. We assayed plasma
for protein biomarkers of liver function and analysed
histological liver sections at 8, 24 and 48 h after adminis-
tration of APAP which confirmed liver injury from 8 h
after APAP dosing (Additional File 8: Figure S5). Ana-
lysis of total plasma cfDNA demonstrated an increase of
~ 100-fold in APAP-dosed mice compared to mice re-
ceiving saline injection, which peaked at 8 h post APAP
dose. cfDNA in hepatocyte-specific knockout mice was
subsequently measured at 8 h, where we also observed
greater than 100-fold increase in the total cfDNA follow-
ing APAP dosing, compared to control mice receiving
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saline only injections. The majority of the increase of
cfDNA in mice following APAP overdose is from fragments
of 170 bp as shown by fragment analysis (Additional File 9:
Figure S6), indicating minimal contamination from lysed
leukocytes in these samples during sample pre-processing.
An increase of the liver biomarkers, ALT and AST, and
histological analysis of mouse liver tissues confirmed the
presence of liver injury (Fig. 4). Furthermore, quantification
Fig. 1 Validation of ddPCR assays on gDNA containing 1lox or 2lox alleles. a 1lox ddPCR assay specifically amplified gDNA containing 1lox alleles,
b 2lox ddPCR assay amplified gDNA containing 2lox alleles with less than 0.1% of positive droplets from 1lox gDNA. The pink line shows the
threshold between positive and negative droplets at fluorescence amplitude 3000. c Dilution experiment showed both assays robustly detected
less than 30 targets. The estimated number of targets refers to the number of successful amplifications as indicated by positive droplets in ddPCR
following Poisson correction to estimate the real input of DNA fragment. Each dot showed mean of 1lox or 2lox copies measured by ddPCR
assays in six replicates. Error bars showed standard error
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of liver-specific cfDNA at 8 h post APAP dosing in
hepatocyte-specific knockout mice shows hepatocyte
contribution to cfDNA increased to 77.9%, compared to
4.2% in non-treated healthy mice (Fig. 4g, Additional File 10:
Figure S7).
Analysis cfDNA in patients with APAP overdose
To demonstrate potential applicability of our findings to
APAP overdose in humans, we measured the total
amount of cfDNA and protein liver function biomarkers
in the serum of healthy volunteers (n = 11) and APAP
overdose patients (n = 8), a subset of which (n = 4) were
not exhibiting clinically apparent liver injury based on
serum ALT levels (Additional File 11: Table S4). On
average, the concentration of cfDNA in the APAP over-
dose patients increased by ~ 126-fold (Fig. 5a). In pa-
tients with clinically apparent liver injury (high ALT),
total cfDNA increased by ~ 234-fold, whereas patients
without clinically apparent liver injury (normal ALT)
demonstrated mean total cfDNA increase of ~ 18-fold
compared to healthy volunteers (Fig. 5a). The increase
in total cfDNA following APAP overdose in patients was
consistent with the increase in cfDNA following APAP
in C57BL/6 and hepatocyte-specific knockout mice, indi-
cating the potential of analysis of cfDNA as a clinical
biomarker in APAP overdose.
To further assess the utility of cfDNA as a clinical
biomarker, we compared the serum cfDNA concentra-
tion with other conventional biomarkers of liver func-
tion. Total cfDNA was higher in all patients with APAP
overdose than in healthy volunteers, although two sam-
ples, one from an overdose patient with normal ALT
(cfDNA = 192.87) and one healthy volunteer (cfDNA =
188.17) showed similar cfDNA concentrations (Fig. 5b).
Total concentration of cfDNA also correlated with
levels of glutamate dehydrogenase (GLDH), a novel
APAP overdose biomarker that measures mitochondrial
damage (Spearman correlation 0.85, p-value < 0.01)
with the (Fig. 5c). Analysis of paired serum samples
from three APAP overdose patients before and after
treatment with NAC showed a decrease in total cfDNA
concentration after treatment. The decrease of total
cfDNA was consistent with the decrease in serum ALT
levels, indicating the potential utility of total cfDNA to
monitor the efficacy of treatment in APAP overdose
patients (Additional File 12: Table S5).
Fig. 2 Analysis of Cre recombination in tissues of knockout mouse lines. a ddPCR measurement of 1lox allele and 2lox allele in tissues where
recombination was expected vs. not expected for each knockout line (n > 10 mice for each line). p-value obtained from a Mann-Whitney U test b
Representative images for confirmation of Cre recombination in tissues shown by fluorescence imaging. Left to right: liver of a AlbCre;mT/mG
mouse, liver of a mT/mG mouse, heart of a cTnTCre;mT/mG mouse, heart of a mT/mG mouse. Green colour in the tissues derived from the
expression of mG, and red from mT. c Representative bar charts of % recombination showing specificity of Cre recombination in a hepatocyte-
and cardiomyocyte-specific knockout mouse across many tissues shown by ddPCR assay
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Specific analysis of liver contributions to the cfDNA
pool, measured by ddPCR, showed the percentage of
liver-specific cfDNA fragments increased by ~ 175-fold
in patients with clinically apparent liver injury compared
to healthy volunteers, but no increase in liver-specific
cfDNA was observed in overdose patients without clinic-
ally apparent liver injury (normal ALT) (Fig. 5d, e).
Although GLDH levels were increased in APAP over-
dose patient with normal ALT, analysis of liver-specific
cfDNA indicated that the cfDNA did not originate from
liver tissue (Fig. 5f).
Discussion
Our study demonstrates the utility of tissue-specific
knockout mouse models as a platform to examine the
tissue origins of cfDNA. Here, we present the first abso-
lute, direct measurement of the tissue origins of cfDNA
in healthy mice, as well as post-APAP overdose. Our
data show that hematopoietic cells, including myeloid,
lymphoid and erythroid cells, are the major components
of cfDNA in the healthy state, with a minor contribution
from liver and no detectable contribution from cardio-
myocytes and skeletal muscle cells. Our results show
concordance with other indirect methods, such as nu-
cleosomal profiling and methylation analysis, that have
assessed the tissue origins of cfDNA [7, 21–23], although
these studies show considerable variation in the esti-
mates of tissue origin, which may in part be due to the
indirect or relative measurement methods [24]. Analysis
of cfDNA using tissue-specific knockout mice had previ-
ously been performed to explore the utility of total
cfDNA and circulating tumour DNA (ctDNA) as an
early-stage biomarker of cancer [38]. Measurement of
tissue origins of cfDNA in knockout mouse models is
direct and specific for the tissue of interest and benefits
from the ability to control external variables, further re-
ducing sample variability. This experimental design may
therefore be more accurate and less error-prone than
indirect relative methods. The utilisation of knockout
mouse models can be extended to study the tissue ori-
gins of cfDNA from not only haematopoietic cells, but
also other cells of interest depending on the availability
of Cre-regulated promoter.
We also demonstrate the applicability of this model
system in a pathological scenario. The total concentra-
tion of cfDNA and the hepatocyte-derived fraction of
Fig. 3 The tissue origins of cfDNA in healthy mouse models. a Total amount of cfDNA obtained from a minimum of 10 mice (pooled) per
knockout line measured by qPCR of ACTB gene. b Representative cfDNA fragment analysis from hepatocyte-specific knockout mice. Fragments of
cfDNA followed mono-, di-, and tri- nucleosome fragment sizes, and large cfDNA fragment size, shown by black arrows c Percentage
recombination (1lox%) for each knockout mouse line showing contribution of different cell types to total cfDNA. d A cumulative percentage of
cell/tissue contributions to cfDNA from ddPCR
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cfDNA increased substantially after APAP-induced liver
injury in mice. This large increase in total cfDNA and
hepatocyte-specific cfDNA after APAP overdose demon-
strate the sensitivity of the model system for detecting
perturbations in the origins of cfDNA arising from ex-
ternal stimuli. The study is the first to show the contri-
bution of a specific tissue to the pool of cfDNA using
tissue-specific knockout mice, thereby serving as a gen-
eric proof of concept for investigations of the cellular or-
igins of cfDNA in other physiological and pathological
conditions. This may include exercise, infection, auto-
immunity, trauma, myocardial infarction and transplant-
ation as well as in studies of development and ageing.
Analysis of the tissue origins of cfDNA has the potential
to be applied to any condition associated with cell death
or loss of nuclear DNA, into plasma or other bodily
fluids, such as urine, saliva or cerebrospinal fluid.
APAP overdose is the most common cause of acute
liver failure in the USA and Europe [39]. Previous
studies have suggested the utility of cfDNA as a clinical
biomarker of cell death in a range of clinical conditions
[15, 18], but cfDNA has not previously been studied as a
biomarker of liver damage in APAP overdose. We found
that total concentration of cfDNA robustly distinguished
APAP overdose patients from healthy volunteers. Fur-
ther, total concentration of cfDNA distinguished APAP
overdose patients before and after treatment with NAC,
with a marked fall after NAC treatment. These results
suggest that total cfDNA concentration may reflect ex-
posure to APAP. In overdose patients with raised ALT,
the increase in cfDNA concentration was greater than in
those with normal ALT, although all overdose patients
had a higher cfDNA concentration than healthy volun-
teers. However, whilst there was also a clear increase in
the proportion of cfDNA that originated from liver in
overdose patients with raised ALT concentrations, the
proportion of liver-specific cfDNA was not increased in
overdose patients with normal ALT. This contrasts with
our observation of increased GLDH in all overdose pa-
tients, both those with raised and normal ALT. Previous
studies have proposed GLDH as a marker of liver dam-
age in APAP overdose [40], but these data suggest that
Fig. 4 The tissue origins of cfDNA following APAP overdose in mouse models. Barplots of concentration of blood biomarkers from APAP-injected
hepatocyte-specific knockout mice (n = 4) and saline-treated negative control (n = 10, pooled): a total cell-free DNA, b bilirubin, c AST, d ALT, e
albumin. Data are shown as mean ± standard error. f H&E staining of liver tissues from an APAP-injected hepatocyte-specific knockout mice vs
saline-treated negative control showing acute zone 3 coagulative necrosis typical of APAP hepatotoxicity. g Comparison of hepatocyte cell
contribution in healthy mice vs post APAP overdose (n = 4)
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in APAP patients with normal ALT, the rise in total
cfDNA and GLDH was not liver-derived and may have
been due to damage of tissues other than the liver.
Given that serum GLDH is a measure of mitochondrial
damage [41] and that GLDH is expressed heteroge-
neously across mammalian tissues [42], the increase in
GLDH and cfDNA in patients without clinically overt
liver injury may reflect release of cfDNA from other tis-
sues, for which further pre-clinical and clinical work is
indicated to establish the source.
Despite the novel approach of absolute and direct
measurement of cfDNA, our study is limited by issues
that are widely acknowledged in the field of cfDNA re-
search [43]. Firstly, low cfDNA concentration and low
plasma volume of mice means pooling of cfDNA from at
least 10 mice was necessary to obtain sufficient material
for ddPCR assay measurement. In addition, haemolysis
and contamination of large cfDNA fragments that arises
from lysis of blood cells during sample processing may
have led to an overestimation of the fraction of cfDNA
derived from white blood cells. Finally, the contribution
of cells measured in this study is dependent upon the ac-
tivity and specificity of Cre-recombinase, which varies
between knockout lines.
Prior to wider application of cfDNA assays in the
clinic, it will be important to understand the sources of
variability in cfDNA concentrations in healthy subjects
and the origins of cfDNA in the presence of physio-
logical stimuli such as exercise and common disorders
(e.g. upper respiratory infection). Whilst studies in
humans can give indirect measures of tissue origins of
cfDNA, optimal assay design and interpretation will re-
quire greater understanding of the effects of develop-
mental stage and physiological and pathological state, as
well as the mechanism of release for injured or dying tis-
sue. These factors are difficult to study in humans and
the model system reported here may yield insights that
are of value for clinical assay development. For the spe-
cific clinical scenario studied here, APAP overdose, in
which current patient stratification is acknowledged to
be sub-optimal [44], follow-up studies in larger numbers
will be needed for validation and formal assessment of
sensitivity, specificity and predictive power.
Conclusions
Absolute measurement of the tissue origins of cfDNA
in the healthy state showed major contributions from
hematopoietic cells, minor contributions from hepato-
cytes, and no detectable contribution from cardiac
and skeletal muscle. The analysis of cfDNA is a can-
didate biomarker for stratification of APAP overdose
patients.
Fig. 5 Analyses of cfDNA and other liver biomarkers in clinical samples. Comparison of (a) total concentration of cfDNA between healthy
volunteers (HV), APAP overdose patients with normal ALT (AON) and high ALT (AOH) and (b) comparison of serum ALT and total concentrations
of cfDNA, (c) comparison of serum GLDH and total concentrations of cfDNA, (d) comparison of percentage of liver-specific cfDNA between
samples, (e) comparison of serum ALT and percentage of liver-specific cfDNA, (f) comparison of serum GLDH and percentage of liver-specific
cfDNA. Statistical significance for panel (a) and (d) were obtained from Mann-Whitney U test and for panel (b), (c), (e), (f) from Spearman’s rank
correlation coefficient
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Additional file 1: Figure S1. A schematic representation of the overall
strategy for absolute quantitation of the tissue origins of cell-free DNA.
Description of data: A conditional knockout is generated in the tissue of
interest (e.g. liver) for each mouse model, containing a tissue/cell-specific
Cre recombinase and the reporter gene floxed mT/mG. Cre recombin-
ation occurs in target cells/tissues, causing deletion of a loxP site and the
mT gene, leaving one loxP site in the DNA (1lox), and enabling the ex-
pression of the mG gene as opposed to other tissues in the body that
contain two loxP sites (2lox). Histology and DNA analysis are performed
in mouse tissues to confirm Cre recombination. Cell-free DNA, containing
a mixture of 1lox and 2lox alleles released by various tissues through nor-
mal tissue turnover, can be extracted and analysed to reveal absolute
contribution of cell-type/tissue of interest.
Additional file 2: Figure S2. Body weight measurements from different
mouse lines at 10–12 week old. Description of data: Body weight of mice
(n > 10) ranges between 20.6 and 31.9 g. Tissue knockout mouse lines
showed similar body weight to non-knockout control (no Cre).
Additional file 3: Table S1. Oligonucleotides for amplification of
1lox and 2lox mT/mG gene. Description of data: 1lox assay
consisted of mTmGF1, mTmGR and mTmGP. 2lox assay consisted of
mTmGF2, mTmGR, mTmGP. FAM: 6-carboxyfluorescein; BHQ: black
hole quencher. Amplicon length for 1lox and 2lox assays are 124 bp.
(XLS 25 kb)
Additional file 4 Table S2. Primer pairs and probes for amplification of
liver and non-liver DNA fragments using methylation ddPCR. Description
of data: Amplification of liver and non-liver DNA fragments was per-
formed as previously described [37].
Additional file 5: Figure S3. Specificity of Cre recombination across
16 mouse tissues in four knockout lines. Description of data:
Knockout lines from top to bottom: myeloid, lymphoid, erythroid and
striated muscle.
Additional file 6: Figure S4. Total amount of cfDNA extracted from a
single mouse, and pools of 5, and 10 C57BL/6 mice. Description of data:
Total amount of cfDNA from a pool of 10 mice provided sufficient cfDNA
input for at least duplicate measurements using ddPCR (20 ng for a
single measurement of 1lox and 2lox alleles).
Additional file 7: Table S3. Measurements of the tissue origins of
cfDNA in the healthy state between three studies. Description of data: A
comparison of tissue contributions between the present study with 2
other studies in human based on tissue-specific methylation pattern by
Sun et al. [21] and Moss et al. [23].
Additional file 8: Figure S5. The effect of APAP on biomarkers at
different timepoints in C57BL/6 mice. Description of data: The concentration
of cfDNA (A), concentration of alanine aminotransferase (B) and aspartate
aminotransferase (C) peaked at 8 h following APAP dosing and decreased
after 24 and 48 h. The levels of albumin (D) and bilirubin (E) were unaffected
by APAP dosing, indicating the absence of overt liver failure. Histological
analysis (F) showed that liver damage (acute zone 3 coagulative necrosis
typical of APAP hepatotoxicity) was most severe at 24-h following APAP
compared to other time points.
Additional file 9: Figure S6. Fragment size of cfDNA following APAP
overdose in four mice showed a majority contribution of mononucleosomal
DNA (~ 150 bp).
Additional file 10: Figure S7. The effect of intraperitoneal injection on the
tissue origins of cfDNA Description of data: The increase of hepatocyte
contribution in the analysis of the tissue origins of cfDNA 8-h after APAP dosing
in hepatocyte-specific knockout mice was not caused by intraperitoneal injec-
tion, as shown by a decrease of tissue contribution in mice injected with saline.
Additional file 11: Table S4. Measurements of serum biomarkers from
APAP overdose patients and healthy volunteers. Description of data:
Normal range for serum biomarker [45, 46]: Bilirubin (2–17 μmol/l), ALT
(0–45 IU/l), AST (0–35 IU/l), ALP (30–120 IU/l), ALB/Albumin (40–60 g/l),
GLDH (1–10 IU/l).
Additional file 12: Table S5. Comparison of biomarkers in APAP
overdose patients before and after treatment with NAC Description of
data: Total cfDNA was measured using a single-locus qPCR of the human
beta-actin gene (ACTB). The normal range for serum ALT is 0–45 IU/l.
Abbreviations
ACTB: beta-actin; ALB: Albumin; ALT: Alanine aminotransferase;
APAP: Paracetamol/ acetaminophen/N-acetyl-para-aminophenol;
AST: Aspartate aminotransferase; BHQ: Black hole quencher; cfDNA: Cell-free
DNA; ddPCR: Droplet-digital PCR; FAM: 6-carboxyfluorescein; gDNA: Genomic
DNA; GFP: Green fluorescent protein; GLDH: Glutamate dehydrogenase;
H&E: Hematoxylin and eosin; IP: Intraperitoneal; mG: Cell membrane-localised
enhanced green fluorescent protein; mT: Cell membrane-localised tdTomato;
1lox: Recombined floxed allele; 1lox%: Percentage recombination of floxed
alleles; 2lox: Unrecombined floxed allele
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